Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients

NCT01830595 is registered in ClinicalTrials.gov with Jason Baker as lead sponsor.

NCT NCT01830595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01830595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Lead sponsor
Jason Baker
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
January 31, 2018
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection